These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 8538187)

  • 1. Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia.
    De Palo G; Veronesi U; Marubini E; Camerini T; Chiesa F; Nava M; Formelli F; Del Vecchio M; Costa A; Boracchi P
    J Cell Biochem Suppl; 1995; 22():11-7. PubMed ID: 8538187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retinoids in cancer chemoprevention. Clinical trials with the synthetic analogue fenretinide.
    Costa A; De Palo G; Decensi A; Formelli F; Chiesa F; Nava M; Camerini T; Marubini E; Veronesi U
    Ann N Y Acad Sci; 1995 Sep; 768():148-62. PubMed ID: 8526344
    [No Abstract]   [Full Text] [Related]  

  • 3. Prospects of chemoprevention of human cancers with the synthetic retinoid fenretinide.
    Costa A; Formelli F; Chiesa F; Decensi A; De Palo G; Veronesi U
    Cancer Res; 1994 Apr; 54(7 Suppl):2032s-2037s. PubMed ID: 8137334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fenretinide (4-HPR) in chemoprevention of oral leukoplakia.
    Chiesa F; Tradati N; Marazza M; Rossi N; Boracchi P; Mariani L; Formelli F; Giardini R; Costa A; De Palo G
    J Cell Biochem Suppl; 1993; 17F():255-61. PubMed ID: 8412202
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results.
    Chiesa F; Tradati N; Marazza M; Rossi N; Boracchi P; Mariani L; Clerici M; Formelli F; Barzan L; Carrassi A
    Eur J Cancer B Oral Oncol; 1992 Oct; 28B(2):97-102. PubMed ID: 1306735
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality control for HPLC assay and surrogate end point biomarkers from the fenretinide (4-HPR) breast cancer prevention trial.
    Formelli F
    J Cell Biochem Suppl; 2000; 34():73-9. PubMed ID: 10762018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results.
    Chiesa F; Tradati N; Grigolato R; Boracchi P; Biganzoli E; Crose N; Cavadini E; Formelli F; Costa L; Giardini R; Zurrida S; Costa A; De Palo G; Veronesi U
    Int J Cancer; 2005 Jul; 115(4):625-9. PubMed ID: 15700313
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenretinide and cancer prevention.
    Torrisi R; Decensi A
    Curr Oncol Rep; 2000 May; 2(3):263-70. PubMed ID: 11122852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fenretinide breast cancer prevention trial: drug and retinol plasma levels in relation to age and disease outcome.
    Formelli F; Camerini T; Cavadini E; Appierto V; Villani MG; Costa A; De Palo G; Di Mauro MG; Veronesi U
    Cancer Epidemiol Biomarkers Prev; 2003 Jan; 12(1):34-41. PubMed ID: 12540501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fenretinide activity in retinoid-resistant oral leukoplakia.
    Lippman SM; Lee JJ; Martin JW; El-Naggar AK; Xu X; Shin DM; Thomas M; Mao L; Fritsche HA; Zhou X; Papadimitrakopoulou V; Khuri FR; Tran H; Clayman GL; Hittelman WN; Hong WK; Lotan R
    Clin Cancer Res; 2006 May; 12(10):3109-14. PubMed ID: 16707609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of fenretinide on ovarian carcinoma occurrence.
    De Palo G; Mariani L; Camerini T; Marubini E; Formelli F; Pasini B; Decensi A; Veronesi U
    Gynecol Oncol; 2002 Jul; 86(1):24-7. PubMed ID: 12079295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer.
    Veronesi U; Mariani L; Decensi A; Formelli F; Camerini T; Miceli R; Di Mauro MG; Costa A; Marubini E; Sporn MB; De Palo G
    Ann Oncol; 2006 Jul; 17(7):1065-71. PubMed ID: 16675486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention trial of contralateral breast cancer with fenretinide. Rationale, design, methodology, organization, data management, statistics and accrual.
    De Palo G; Camerini T; Marubini E; Costa A; Formelli F; Del Vecchio M; Mariani L; Miceli R; Mascotti G; Magni A; Campa T; Di Mauro MG; Attili A; Maltoni C; Del Turco MR; Decensi A; D'Aiuto G; Veronesi U
    Tumori; 1997; 83(6):884-94. PubMed ID: 9526578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accrual issues for chemoprevention trials: the example of the 4-HPR study for the prevention of contralateral breast cancer.
    Camerini T; De Palo G; Mariani L; Marubini E; Costa A; Veronesi U
    Tumori; 1999; 85(4):299-303. PubMed ID: 10587038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The synthetic retinoid fenretinide lowers plasma insulin-like growth factor I levels in breast cancer patients.
    Torrisi R; Pensa F; Orengo MA; Catsafados E; Ponzani P; Boccardo F; Costa A; Decensi A
    Cancer Res; 1993 Oct; 53(20):4769-71. PubMed ID: 8402658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group.
    Clark LC; Combs GF; Turnbull BW; Slate EH; Chalker DK; Chow J; Davis LS; Glover RA; Graham GF; Gross EG; Krongrad A; Lesher JL; Park HK; Sanders BB; Smith CL; Taylor JR
    JAMA; 1996 Dec; 276(24):1957-63. PubMed ID: 8971064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Veronesi U; De Palo G; Marubini E; Costa A; Formelli F; Mariani L; Decensi A; Camerini T; Del Turco MR; Di Mauro MG; Muraca MG; Del Vecchio M; Pinto C; D'Aiuto G; Boni C; Campa T; Magni A; Miceli R; Perloff M; Malone WF; Sporn MB
    J Natl Cancer Inst; 1999 Nov; 91(21):1847-56. PubMed ID: 10547391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
    Sabichi AL; Modiano MR; Lee JJ; Peng YM; Xu MJ; Villar H; Dalton WS; Lippman SM
    Clin Cancer Res; 2003 Jul; 9(7):2400-5. PubMed ID: 12855611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.
    Ménard S; Camerini T; Mariani L; Tomasic G; Pilotti S; Costa A; De Palo G; Veronesi U
    J Natl Cancer Inst; 2001 Feb; 93(3):240-1. PubMed ID: 11158198
    [No Abstract]   [Full Text] [Related]  

  • 20. Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?
    Cazzaniga M; Varricchio C; Montefrancesco C; Feroce I; Guerrieri-Gonzaga A
    J Biomed Biotechnol; 2012; 2012():172897. PubMed ID: 22500077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.